| Who should pay for clinical research? |
| GP Canellos |
|
JCO Nov 1 1990: 1775–1776.
[PDF]
|
 |
|
Treatment of testicular cancer: a new and improved model |
| |
LH Einhorn |
| |
JCO Nov 1 1990: 1777–1781.
[Abstract]
[PDF]
|
|
|
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer |
| |
R Wallerstein, Jr, G Spitzer, F Dunphy, S Huan, G Hortobagyi, J Yau, A Buzdar, F Holmes, R Theriault, and M Ewer |
| |
JCO Nov 1 1990: 1782–1788.
[Abstract]
[PDF]
|
|
|
Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix |
| |
J Bourhis, MG Le, M Barrois, A Gerbaulet, D Jeannel, P Duvillard, V Le Doussal, D Chassagne, and G Riou |
| |
JCO Nov 1 1990: 1789–1796.
[Abstract]
[PDF]
|
|
|
High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association |
| |
HB Muss, LD Case, RL Capizzi, MR Cooper, J Cruz, D Jackson, F Richards, 2d, BL Powell, CL Spurr, and D White |
| |
JCO Nov 1 1990: 1797–1805.
[Abstract]
[PDF]
|
|
|
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer |
| |
D Nielsen, JB Jensen, P Dombernowsky, O Munck, J Fogh, I Brynjolf, H Havsteen, and M Hansen |
| |
JCO Nov 1 1990: 1806–1810.
[Abstract]
[PDF]
|
|
|
Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study |
| |
CW Taylor, J Crowley, SK Williamson, TP Miller, SA Taylor, TG Giri, RL Stephens, and RB Livingston |
| |
JCO Nov 1 1990: 1811–1817.
[Abstract]
[PDF]
|
|
|
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study |
| |
RD Issels, SW Prenninger, A Nagele, E Boehm, H Sauer, KW Jauch, H Denecke, H Berger, K Peter, and W Wilmanns |
| |
JCO Nov 1 1990: 1818–1829.
[Abstract]
[PDF]
|
|
|
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease |
| |
HI Scher, T Curley, N Geller, C Engstrom, DD Dershaw, SY Lin, K Fitzpatrick, J Nisselbaum, M Schwartz, and L Bezirdjian |
| |
JCO Nov 1 1990: 1830–1838.
[Abstract]
[PDF]
|
|
|
Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion |
| |
CL Shalmi, JP Dutcher, DA Feinfeld, KJ Chun, KR Saleemi, LM Freeman, RI Lynn, and PH Wiernik |
| |
JCO Nov 1 1990: 1839–1846.
[Abstract]
[PDF]
|
|
|
Long-term sequelae of conservative treatment by surgery, brachytherapy, and chemotherapy for vulval and vaginal rhabdomyosarcoma in children |
| |
F Flamant, A Gerbaulet, C Nihoul-Fekete, D Valteau-Couanet, D Chassagne, and J Lemerle |
| |
JCO Nov 1 1990: 1847–1853.
[Abstract]
[PDF]
|
|
|
Questionable role of CNS radioprophylaxis in the therapeutic management of childhood rhabdomyosarcoma with meningeal extension |
| |
M Gasparini, F Lombardi, MC Gianni, M Massimino, L Gandola, and F Fossati-Bellani |
| |
JCO Nov 1 1990: 1854–1857.
[Abstract]
[PDF]
|
|
|
Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients |
| |
D Berd, HC Maguire, Jr, P McCue, and MJ Mastrangelo |
| |
JCO Nov 1 1990: 1858–1867.
[Abstract]
[PDF]
|
|
|
Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics |
| |
CA Presant, W Wolf, MJ Albright, KL Servis, R Ring, 3d, D Atkinson, RL Ong, C Wiseman, M King, and D Blayney |
| |
JCO Nov 1 1990: 1868–1873.
[Abstract]
[PDF]
|
|
|
Changes in the clearance of total and unbound etoposide in patients with liver dysfunction |
| |
CF Stewart, SG Arbuck, RA Fleming, and WE Evans |
| |
JCO Nov 1 1990: 1874–1879.
[Abstract]
[PDF]
|
|
|
Clinical evaluation of a side entry access port: a novel dual-lumen venous access device |
| |
TS Ravikumar and J Hollingshead |
| |
JCO Nov 1 1990: 1880–1884.
[Abstract]
[PDF]
|
|
|
A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver |
| |
LD Wagman, MM Kemeny, L Leong, JJ Terz, LR Hill, JD Beatty, WA Kokal, and DU Riihimaki |
| |
JCO Nov 1 1990: 1885–1893.
[Abstract]
[PDF]
|
|
|
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33 |
| |
S Welt, CR Divgi, FX Real, SD Yeh, P Garin-Chesa, CL Finstad, J Sakamoto, A Cohen, ER Sigurdson, and N Kemeny |
| |
JCO Nov 1 1990: 1894–1906.
[Abstract]
[PDF]
|
|
|
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma |
| |
R Ohno, K Okada, T Masaoka, A Kuramoto, T Arima, Y Yoshida, H Ariyoshi, M Ichimaru, Y Sakai, and M Oguro |
| |
JCO Nov 1 1990: 1907–1912.
[Abstract]
[PDF]
|
|
|
The unique aspects of acute promyelocytic leukemia |
| |
RM Stone and RJ Mayer |
| |
JCO Nov 1 1990: 1913–1921.
[Abstract]
[PDF]
|
|
| Hormonal versus chemohormonal adjuvant therapy in node-positive postmenopausal patients |
| AU Haq and MB Haq |
|
JCO Nov 1 1990: 1922a.
[PDF]
|
|
| Chemohormonal therapy for older women with node-positive breast cancer |
| M Brower and SN Rosenthal |
|
JCO Nov 1 1990: 1922b–1923.
[PDF]
|
|
| The reporting of trials of adjuvant therapy for breast cancer |
| IF Tannock |
|
JCO Nov 1 1990: 1923–1924.
[PDF]
|
|
| What determines actual chemotherapy dose intensity? |
| MH Cohen |
|
JCO Nov 1 1990: 1926.
[PDF]
|
|
| Dose intensity in the treatment of diffuse large-cell lymphoma |
| JR Anderson, MT Santarelli, and B Peterson |
|
JCO Nov 1 1990: 1927–1928.
[PDF]
|
|
| Concomitant chemoradiotherapy |
| A Aref |
|
JCO Nov 1 1990: 1928–1930.
[PDF]
|
|
